肿瘤学中的血管靶向治疗
Vascular targeted therapies in oncology.
作者信息
Siemann Dietmar W, Horsman Michael R
机构信息
Department of Radiation Oncology, University of Florida, 2000 SW Archer Road, Gainesville, FL, USA.
出版信息
Cell Tissue Res. 2009 Jan;335(1):241-8. doi: 10.1007/s00441-008-0646-0. Epub 2008 Aug 28.
Abstract
Neovascularization is intimately involved in tumor survival, progression, and spread, factors known to contribute significantly to treatment failures. Thus, strategies targeting the tumor blood vessel support network may offer not only unique therapeutic opportunities in their own right, but also novel means of enhancing the efficacies of conventional anticancer treatments. This article reviews one such therapeutic approach directed at the tumor blood vessel support network. Vascular disrupting therapies seek the destruction of the established neovasculature of actively growing tumors. The goal of these therapies is to cause a rapid and catastrophic shutdown in the vascular function of the tumor in order to arrest the blood flow and produce tumor cell death as a result of oxygen and nutrient deprivation and the build up of waste products.
摘要
新生血管形成与肿瘤的存活、进展和扩散密切相关，而这些因素是导致治疗失败的重要原因。因此，针对肿瘤血管支持网络的策略不仅本身可能提供独特的治疗机会，还可能成为增强传统抗癌治疗效果的新方法。本文综述了一种针对肿瘤血管支持网络的治疗方法。血管破坏疗法旨在破坏活跃生长肿瘤中已形成的新生血管。这些疗法的目标是使肿瘤的血管功能迅速发生灾难性的关闭，从而阻止血流，并由于氧气和营养物质的缺乏以及废物的积累导致肿瘤细胞死亡。
相似文献
1
Vascular targeted therapies in oncology.肿瘤学中的血管靶向治疗
Cell Tissue Res. 2009 Jan;335(1):241-8. doi: 10.1007/s00441-008-0646-0. Epub 2008 Aug 28.
2
Targeting the tumor vascular compartment to improve conventional cancer therapy.靶向肿瘤血管区室以改善传统癌症治疗。
Trends Pharmacol Sci. 2004 Oct;25(10):536-42. doi: 10.1016/j.tips.2004.08.008.
3
Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.肿瘤边缘细胞：从对血管靶向药物耐药到实现肿瘤完全消融
Tumour Biol. 2017 Mar;39(3):1010428317691001. doi: 10.1177/1010428317691001.
4
Computer Simulations of the Tumor Vasculature: Applications to Interstitial Fluid Flow, Drug Delivery, and Oxygen Supply.肿瘤血管系统的计算机模拟：在组织间液流动、药物递送和氧气供应中的应用
Adv Exp Med Biol. 2016;936:31-72. doi: 10.1007/978-3-319-42023-3_3.
5
Physical determinants of vascular network remodeling during tumor growth.肿瘤生长过程中血管网络重塑的物理决定因素。
Eur Phys J E Soft Matter. 2010 Oct;33(2):149-63. doi: 10.1140/epje/i2010-10611-6. Epub 2010 Jul 6.
6
Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.血管异常化：癌症的另一个标志？分子机制与治疗意义。
Curr Opin Genet Dev. 2011 Feb;21(1):73-9. doi: 10.1016/j.gde.2010.10.008. Epub 2010 Nov 22.
7
Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.针对肿瘤微环境设计和开发新型抗血管生成药物以抑制肿瘤生长。
Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Epub 2013 Oct 15.
8
Tumor angiogenesis: a potential target in cancer control by phytochemicals.肿瘤血管生成：植物化学物质在癌症控制中的潜在靶点。
Curr Cancer Drug Targets. 2003 Jun;3(3):205-17. doi: 10.2174/1568009033481985.
9
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases.血管正常化的原则和机制用于癌症和其他血管生成性疾病。
Nat Rev Drug Discov. 2011 Jun;10(6):417-27. doi: 10.1038/nrd3455.
10
Angiogenesis inhibitors. Drug selectivity and target specificity.血管生成抑制剂。药物选择性与靶点特异性。
Curr Pharm Des. 2007;13(27):2795-809. doi: 10.2174/138161207781757033.
引用本文的文献
1
Benzosuberene and Tetracyclic Analogues as Colchicine Site Inhibitors of Tubulin Polymerization.苯并环庚烯及其四环类似物作为微管蛋白聚合的秋水仙碱位点抑制剂。
ACS Med Chem Lett. 2025 May 26;16(6):1098-1107. doi: 10.1021/acsmedchemlett.5c00129. eCollection 2025 Jun 12.
2
Vascularized tumor on a microfluidic chip to study mechanisms promoting tumor neovascularization and vascular targeted therapies.用于研究促进肿瘤新生血管形成机制及血管靶向治疗的微流控芯片上的血管化肿瘤
Theranostics. 2025 Jan 1;15(3):766-783. doi: 10.7150/thno.95334. eCollection 2025.
3
Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules.针对肿瘤血管供应，以增强单次或临床相关分割放疗的疗效。
Int J Mol Sci. 2024 Jul 24;25(15):8078. doi: 10.3390/ijms25158078.
4
Targeting circulating tumor cells to prevent metastases.针对循环肿瘤细胞以预防转移。
Hum Cell. 2024 Jan;37(1):101-120. doi: 10.1007/s13577-023-00992-6. Epub 2023 Oct 24.
5
Synthesis of a boron-containing amidoxime reagent and its application to synthesize functionalized oxadiazole and quinazolinone derivatives.一种含硼偕胺肟试剂的合成及其在合成功能化恶二唑和喹唑啉酮衍生物中的应用。
Tetrahedron Lett. 2022 Mar 2;92. doi: 10.1016/j.tetlet.2022.153657. Epub 2022 Jan 25.
6
3D-Cultured Vascular-Like Networks Enable Validation of Vascular Disruption Properties of Drugs .3D培养的类血管网络可实现对药物血管破坏特性的验证。
Front Bioeng Biotechnol. 2022 Jun 13;10:888492. doi: 10.3389/fbioe.2022.888492. eCollection 2022.
7
Noninvasive imaging of tumor hypoxia after nanoparticle-mediated tumor vascular disruption.纳米颗粒介导的肿瘤血管破坏后肿瘤缺氧的无创成像。
PLoS One. 2020 Jul 24;15(7):e0236245. doi: 10.1371/journal.pone.0236245. eCollection 2020.
8
High glucose concentration produces a short-term increase in pERK1/2 and p85 proteins, having a direct angiogenetic effect by an action similar to VEGF.高葡萄糖浓度会导致 pERK1/2 和 p85 蛋白的短期增加，通过类似于 VEGF 的作用产生直接的血管生成效应。
Acta Diabetol. 2020 Aug;57(8):947-958. doi: 10.1007/s00592-020-01501-z. Epub 2020 Mar 4.
9
Treatment of Hepatocellular Carcinoma by Intratumoral Injection of I-AA98 mAb and Its Efficacy Assessments by Molecular Imaging.瘤内注射I-AA98单克隆抗体治疗肝细胞癌及其分子影像学疗效评估
Front Bioeng Biotechnol. 2019 Nov 14;7:319. doi: 10.3389/fbioe.2019.00319. eCollection 2019.
10
Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery.放射治疗选择性预刺激肿瘤血管增强纳米药物递送。
Sci Rep. 2019 Nov 1;9(1):15844. doi: 10.1038/s41598-019-50538-w.
本文引用的文献
1
An update on the clinical development of drugs to disable tumor vasculature.抗肿瘤血管生成药物临床研发进展。
Expert Opin Drug Discov. 2007 Oct;2(10):1357-67. doi: 10.1517/17460441.2.10.1357.
2
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.血管靶向药物的病理生理效应及其与传统疗法联合应用的意义。
Cancer Res. 2006 Dec 15;66(24):11520-39. doi: 10.1158/0008-5472.CAN-06-2848.
3
On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent.血管破坏剂治疗后循环内皮细胞水平升高的起源及性质
J Clin Oncol. 2006 Aug 20;24(24):4040; author reply 4040-1. doi: 10.1200/JCO.2006.07.1175.
4
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.第二代血管破坏剂OXi4503对肿瘤血管的影响。
Clin Cancer Res. 2006 Jul 1;12(13):4090-4. doi: 10.1158/1078-0432.CCR-06-0163.
5
Current development status of small-molecule vascular disrupting agents.小分子血管破坏剂的当前发展状况。
Curr Opin Investig Drugs. 2006 Jun;7(6):522-8.
6
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.5,6-二甲基呫吨酮-4-乙酸治疗难治性肿瘤：一种血管破坏剂的I期安全性研究
Clin Cancer Res. 2006 Mar 15;12(6):1776-84. doi: 10.1158/1078-0432.CCR-05-1939.
7
Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.磷酸考布他汀A4通过干扰血管内皮钙黏蛋白信号传导，诱导肿瘤新生血管快速消退和肿瘤生长。
J Clin Invest. 2005 Nov;115(11):2992-3006. doi: 10.1172/JCI24586. Epub 2005 Oct 13.
8
Disrupting tumour blood vessels.破坏肿瘤血管。
Nat Rev Cancer. 2005 Jun;5(6):423-35. doi: 10.1038/nrc1628.
9
Differentiation and definition of vascular-targeted therapies.血管靶向治疗的分化与定义
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):416-20.
10
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.联合抗血管生成和血管破坏剂治疗实体瘤的疗效
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1233-40. doi: 10.1016/j.ijrobp.2004.08.002.
Zotero 插件